Affiliation:
1. Department of Otolaryngology-Head and Neck Surgery , University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca , Romania
2. Department of Molecular Sciences , University of Medicine and Pharmacy “Iuliu Hatieganu” , Romania
Abstract
Abstract
Background: Tumor characterization through the study of molecular biology has become an invaluable tool in understanding cancer development and evolution due to its relationship with chromosomal mutations, alterations or aberrations. The purpose of this study was to investigate the involvement of genes such as TLR-4 and DNA repair pathways (XRCC1 and XPD) in laryngeal cancer susceptibility in a Romanian population. Method: We performed a case-control study on 157 laryngeal cancer patients and 101 healthy controls. Genetic testing was carried out using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. Results: We identified the Gln allele of the XPDLys751Gln polymorphism as an individual risk factor in laryngeal cancer development (Gln vs Lys, adjusted OR=1.65, 95%CI=1.13–2.40, P=0.008). Subjects with the mutant homozygote variant (Gln/Gln) had a two fold increase in cancer risk (adjusted OR=2.18, 95%CI=1.06–4.47, p=0.028) when compared to the reference wild type genotype (Lys/Lys). Stratification by sex and age, identified males under 62 years as the most susceptible group with an almost three fold risk (adjusted OR=2.94, 95%CI=1.31–6.59, p=0.007) for the dominant model (Lys/Gln+Gln/Gln). No associations were found for TLR-4Thr399Ile, XRCC1Arg194Trp and XRCC1Arg399Gln. Conclusion: The results of the study show that the XPDLys751Gln polymorphism may be among other independent risk factors for developing laryngeal cancer where as TLR-4Thr399Ile, XRCC1Arg194Trp and XRCC1 Arg399Gln show no such association. However, we consider the relative small number of the subjects selected for this analyses a possible limitation towards the real influence the obtain results may pertain in laryngeal cancer evolution.
Reference51 articles.
1. 1. Sarafoleanu D. Tumorile maligne ale laringelui. In: Sarafoleanu C, editor. Esenţialul in laringologie. Editura Academiei Romane. Bucuresti. 2007. p. 322–351.
2. 2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436–44. DOI: 10.1038/nature07205
3. 3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. DOI: 10.1016/j.cell.2011.02.013
4. 4. Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Molecular Cancer. 2019 Mar 30;18(1):63. DOI: 10.1186/s12943-019-0983-5
5. 5. Barnes L, Tse LLY, Hunt Jl, Brandwein-Gensler M, Urken M, Slootwef P, et al. Tumours of the hypopharynx, larynx and trachea: Introduction. In: Barnes L, Evenson JW, Reichart P, Sidransky D, editors. World Health Classification of Tumors Pathology and Genetics of Head and Neck Tumors. IARC Press. Lyon. 2005. p.109–120.